Dotinurad
Sponsors
Crystalys Therapeutics Inc., Mizoguchi Tatsuya, Dohi Kaoru, Eisai Co., Ltd., Urica Therapeutics Inc.
Conditions
Atrial Fibrillation
Atrial FibrillationGoutHealthy VolunteersHeart Failure with Hyperuricemia
Dotinurad, Heart Failure, Hyperuricemia, eGFRHypertensionHyperuricemiaHyperuricemia associated with gout.Hyperuricemia or Gout
Phase 1
A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants
CompletedNCT05278676
Start: 2022-07-01End: 2022-12-13Updated: 2023-09-14
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
CompletedNCT06056570
Start: 2023-10-04End: 2024-07-09Updated: 2026-06-10
Phase 2
Phase 3
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
CompletedNCT05007392
Start: 2021-12-21End: 2023-06-14Updated: 2025-07-30
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
RecruitingNCT07089888
Start: 2025-08-04End: 2027-12-31Target: 250Updated: 2026-09-03
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RecruitingNCT07089875
Start: 2025-08-01End: 2027-11-29Target: 500Updated: 2026-09-03
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
RecruitingCTIS2024-520206-19-00
Start: 2025-12-02Target: 65Updated: 2025-12-15
Phase 4
Effect of Dotinurad in Hyperuricemia With Hypertension
RecruitingNCT06834230
Start: 2025-03-28End: 2030-03-31Target: 360Updated: 2025-12-15
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
Not yet recruitingNCT07661030
Start: 2026-07-30End: 2027-07-30Target: 142Updated: 2026-06-22